0SZI Stock Chart & Stats
$9.22
-$0.08(-0.92%)
At close: 4:00 PM EDT
$9.22
-$0.08(-0.92%)
Day’s Range― - ―
52-Week Range$7.13 - $24.50
Previous CloseN/A
Volume5.39K
Average Volume (3M)4.42K
Market Cap
$196.70M
Enterprise Value$68.37
Total Cash (Recent Filing)$117.94M
Total Debt (Recent Filing)$4.26M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Nov 10, 2026EPS Estimate
-1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.68
Shares Outstanding19,341,293
10 Day Avg. Volume2,270
30 Day Avg. Volume4,422
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.68
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$37.38Price Target Upside305.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-5.21
Revenue Forecast (FY)$1.67M
Bulls Say, Bears Say
Bulls Say
Regulatory Progress (Phase 3 Clearance)FDA clearance to start a registrational TEMPO-1 Phase 3 study materially reduces near-term regulatory uncertainty and formalizes a path to approval. This durable milestone enables definitive efficacy assessment, informs commercial planning, and supports partnership or licensing options over the next 2–6 months.
Promising Clinical Efficacy (CRB-701)Robust Phase 1/2 response rates and durable responses for CRB-701 indicate meaningful clinical activity in HPV-driven tumors. The biomarker signal (Nectin-4/HPV) and manageable safety support targeted development and increase the probability that registrational trials can demonstrate benefit, strengthening long-term commercial prospects.
Near-term Liquidity RunwayA stated cash balance and management guidance providing runway into 2028 gives the company the financial flexibility to complete key registrational starts and data readouts without immediate fundraising. That improves execution visibility and reduces short-term dilution risk while late-stage programs advance.
Bears Say
Pre‑revenue StatusThe absence of product revenue means long-term value depends entirely on clinical success and external financing. This structural reliance on binary trial outcomes increases execution risk: failures or delays can rapidly erode valuation and impede the firm's ability to sustain operations without capital raises.
Accelerating Cash BurnSharply worsening operating and free cash flow indicate rising development spend and resource consumption. Persistently negative cash generation increases the probability of future capital raises, which can dilute shareholders and constrain strategic optionality for advancing multiple programs concurrently over the medium term.
Balance‑Sheet Volatility & Funding DependenceDeclining equity and prior periods of negative equity reflect balance-sheet volatility tied to cumulative losses. For a development-stage biotech, this structural fragility raises the likelihood of future financing under less favorable terms, and can limit negotiating leverage in partnerships or M&A discussions.
Corbus Pharmaceuticals News
0SZI FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest share price was $7.13 and its highest was $24.50 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Corbus Pharmaceuticals’s market cap is $196.70M.
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is Nov 10, 2026 which is in 91 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -$1.81 earnings per share for the quarter, missing the consensus estimate of -$1.259 by -$0.551.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -1.15.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 19,341,293 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$1.81 in its last earnings report, missing expectations of -$1.259. Following the earnings report the stock price went up 0.521%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0SZI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corbus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.38 (305.37% Upside)
$37.38 (305.37% Upside)
Insider Transactions
Bought Shares
Worth $101.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.25%
Trailing 12-Months
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
0SZI Stock 12 Month Forecast
Average Price Target
$37.38
▲(305.37% Upside)